Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: To evaluate structural and visual functional parameters in ethambutol-related toxic optic neuropathy (EON).
Methods: In this prospective study, we recruited 95 adults with EON presenting within 1 month of onset and 100 age-matched healthy controls. Best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study chart), colour vision (Ishihara pseudoisochromatic plates), contrast sensitivity (Pelli-Robson chart), Humphrey visual field analysis (HVF 30-2 Swedish Interactive Threshold Algorithm-FAST), visual evoked response and spectral domain optical coherence tomography for macular ganglion cell-inner plexiform layer (mGC-IPL), retinal nerve fibre layer (RNFL) and papillomacular bundle (PMB) analyses were done at baseline, 3 months and 6 months.
Results: Almost 52% eyes showed significant visual improvement of ≥ 2 Snellen lines after stopping the drug. RNFL (cases-100.84±21.87 µm vs controls-98.05±7.21 µm; p=0.37) and PMB thickness (cases-51.10±17.26 µm vs controls-53.45±6.42 µm; p=0.19) in cases were comparable with controls at baseline, but showed significant thinning at 6 months follow-up (RNFL -83.77±21.06 µm; PMB-30.96±11.02 µm; p<0.0001 for both). Average GC-IPL thickness (cases-29.66±6.86 µm; controls-39.68±2.59 µm) and ganglion cell-inner plexiform layer (GCL) volume (cases-0.85±0.17 mm; controls-1.08±0.069 mm) was significantly less as compared with controls (p<0.0001 for all) at baseline and showed significant further deterioration on follow-up (p<0.001 for all). The average GC-IPL thickness (p value :<0.0001, r:-0.31), GCL volume (p value :<0.000, r:-0.29) and PMB thickness (p value :0.043, r:-0.14) showed a significant negative correlation with final vision at 6 months.
Conclusion: Progressive structural damage despite visual improvement raises concern about the irreversible nature of EON. PMB, GC-IPL thickness and GCL volume are better predictors of visual recovery in EON.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjo-2025-327475 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MetabOCT: a clinical trial looking for a metabolomic signature predicting the onset of Leber's hereditary optic neuropathy in healthy MtDNA mutations carriers.
Metabolomics
September 2025
Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, Angers, France.
Introduction: The definition of Leber's hereditary optic neuropathy (LHON) does not take into account a preclinical phase during which the thickness of retinal nerve fiber layer (RNFL) is increased, prior to optic nerve atrophy, reducing the chances of visual recovery.
Objectives: Search for a metabolomic signature characterizing this preclinical phase and identify biomarkers predicting the risk of LHON onset.
Methods And Results: The blood and tear metabolomic profiles of 90 asymptomatic LHON mutation carriers followed for one year will be explored as a function of RNFL thickness and compared to those of a healthy control.
[Chinese expert consensus on the diagnosis and treatment of normal tension glaucoma (2025)].
Zhonghua Yan Ke Za Zhi
September 2025
The prevalence of normal tension glaucoma (NTG) in China stands at 1%. The inappropriate demarcation of normal intraocular pressure values may lead to misdiagnosis. The Glaucoma Group of Ophthalmology Branch of Chinese Medical Association released the consensus on the diagnosis and treatment of NTG in 2019, which established important clinical guidelines for the NTG management.
View Article and Find Full Text PDFTargeted decompression to address long-standing anatomical distortion in a case of extensive, bilateral en plaque meningiomas: illustrative case.
J Neurosurg Case Lessons
September 2025
Department of Neurosurgery, Kantonsspital Aarau, Switzerland.
Background: Meningioma en plaque (MEP) is a rare subtype of meningioma with a carpet-like growth pattern, often causing hyperostosis. Even rarer is the presentation of bilateral MEP posing diagnostic and therapeutic challenges. Management of MEP usually entails early complete resection.
View Article and Find Full Text PDF[Electrophysiological methods in the diagnosis and monitoring of glaucoma].
Vestn Oftalmol
September 2025
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Primary open-angle glaucoma (POAG) is characterized by chronic progressive damage to the retinal ganglion cell layer (GCL) and their axons, leading to gradual visual function loss. Currently, the gold standards for structural and functional assessment of the retina in glaucoma are static automated perimetry (SAP) and optical coherence tomography (OCT). However, in clinical practice, data from SAP and OCT may be insufficient to reliably determine the stage of glaucomatous optic neuropathy, monitor its progression, or differentiate it from other causes of visual dysfunction.
View Article and Find Full Text PDF[The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma].
Vestn Oftalmol
September 2025
OOO Diagnosticheskij tsentr Zreniye, Saint Petersburg, Russia.
Objective: This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG).
Material And Methods: The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally).